Takeda Pharmaceutical Company (TAK) is betting big on artificial intelligence to speed up how it discovers new drugs. The Japanese pharmaceutical giant announced Monday it's partnering with Iambic, a San Diego-based AI startup, in a collaboration that could be worth more than $1.7 billion if everything goes according to plan.

Here's the idea: Takeda will tap into Iambic's AI drug discovery models to advance high-priority small molecule programs, starting with oncology, gastrointestinal, and inflammation therapeutic areas. The company will also get access to NeuralPLexer, which is Iambic's model for predicting protein-ligand complexes—essentially helping scientists figure out how drug molecules will interact with their targets in the body.

Founded in 2020, Iambic is a clinical-stage company that combines AI predictions with fully integrated, high-throughput automated wet lab capabilities. It's this Design-Make-Test-Analyze cycle that the company says can dramatically accelerate how quickly programs move forward.

The Economics Behind the Deal

Iambic will receive upfront payments, research costs, and technology access fees right away. But the real money comes later—the startup is eligible for success-based milestone payments that could exceed $1.7 billion, plus royalties on net sales of any products that emerge from the collaboration.

"Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates," said Tom Miller, Co-Founder and CEO of Iambic.

Chris Arendt, Chief Scientific Officer and Head of Research at Takeda, explained the strategic rationale: "Iambic's small molecule platform aligns with this ambition and offers the potential to de-risk candidate selection, improve probability of success, and more quickly advance select programs from early project start to IND."

Why This Matters for Drug Development

The pharmaceutical industry is increasingly turning to AI to compress timelines and reduce costs. Traditional drug discovery typically takes around six years before a compound reaches clinical trials, Miller told Reuters. Iambic claims its approach can shrink that timeline to less than two years—a potentially game-changing acceleration.

But speed isn't everything. Takeda's Arendt emphasized that while AI can help you move faster in small-molecule drug development, molecular quality remains equally critical. The real value is getting better candidates into trials sooner, not just getting more candidates there faster.

Drug developers across the industry are making similar bets, with experts predicting AI could cut discovery timelines in half over the coming years. For pharmaceutical companies facing patent cliffs and ballooning R&D costs, that kind of efficiency gain could be transformative.

TAK Price Action: Takeda Pharmaceutical (TAK) shares were down 1.26% at $17.66 at the time of publication on Monday. The stock is approaching its 52-week high of $17.98, according to market data.